Free tool
Stocks above their 200-day average
We cover 33 companies trading above their own 200-day average. The median market value in the group is $10.57B. Across the group, the median move over the past trading day is +0.52%. 100% of the 33 with a 200-day average trade above it. Price change over the past year runs from −10.9% to +93.1% across the middle 80 percent of the group, with a median of +11.8%.
Other lists in this group
Table
33 of 10,735 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| ABT | Abbott Laboratories | $198.74B | Large cap | −11.83% | Oct 14, 2026 |
| DAP.DE | Danaher Corporation | $151.59B | Large cap | +6.90% | Oct 20, 2026 |
| DHR | Danaher Corporation | $151.40B | Large cap | +5.61% | Oct 20, 2026 |
| MDT | Medtronic plc | $117.78B | Large cap | +2.29% | Sep 1, 2026 |
| 2M6.DE | Medtronic plc | $117.57B | Large cap | +2.65% | Sep 1, 2026 |
| ELV | Elevance Health, Inc. | $87.30B | Large cap | +32.12% | Oct 21, 2026 |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% | Oct 22, 2026 |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% | Oct 20, 2026 |
| WST | West Pharmaceutical Services, Inc. | $24.63B | Large cap | +42.61% | Oct 22, 2026 |
| DIM.PA | Sartorius Stedim Biotech S.A. | $21.78B | Large cap | +11.64% | Oct 22, 2026 |
| 56S1.DE | Sartorius Stedim Biotech S.A. | $21.77B | Large cap | +11.32% | Oct 22, 2026 |
| MEDP | Medpace Holdings, Inc. | $17.28B | Large cap | +30.74% | Oct 19, 2026 |
| SRT.DE | Sartorius Aktiengesellschaft | $15.54B | Large cap | +21.79% | Oct 22, 2026 |
| RVTY | Revvity, Inc. | $13.93B | Large cap | +42.93% | Oct 26, 2026 |
| ICLR | ICON Public Limited Company | $13.03B | Large cap | −2.91% | Oct 21, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $12.70B | Large cap | +11.85% | Oct 26, 2026 |
| MOH | Molina Healthcare, Inc. | $10.57B | Large cap | +13.35% | Oct 21, 2026 |
| HQY | HealthEquity, Inc. | $8.75B | Mid cap | +18.69% | Aug 27, 2026 |
| RHC.AX | Ramsay Health Care Limited | $8.27B | Mid cap | +50.11% | Aug 27, 2026 |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% | Oct 21, 2026 |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% | Sep 4, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% | Oct 8, 2026 |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% | Oct 8, 2026 |
| 3549.T | Kusuri No Aoki Holdings Co., Ltd. | $2.44B | Mid cap | +5.23% | Oct 1, 2026 |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% | Sep 29, 2026 |
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | +1.03% | Aug 27, 2026 |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% | Aug 27, 2026 |
| EKTA-B.ST | Elekta AB (publ) | $2.20B | Mid cap | +26.10% | Aug 27, 2026 |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% | Oct 21, 2026 |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% | Sep 29, 2026 |
| ONCIN.OL | Oncoinvent ASA | $43.71M | Micro cap | +10.90% | Aug 27, 2026 |
| INTEG-B.ST | Integrum AB (publ) | $24.72M | Micro cap | −79.55% | Sep 3, 2026 |
| INM | InMed Pharmaceuticals Inc. | $7.64M | Micro cap | −36.44% | Sep 23, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.